County of San Diego Monthly STD Report

Volume 17, Issue 6: Data through January 2025; Report released July 2, 2025.

Table 1. STDs Reported Among County of San Diego Residents, by Month and Previous 12 Months Combined.

	2024		2025	
	January	*Previous 12-Month Period**	*January*	*Previous 12-Month Period**
Chlamydia	1501	17510	1340	15931
Female age 18-25	484	5642	420	5268
Female age ≤ 17	46	637	58	579
Male rectal chlamydia	150	1703	85	1126
Gonorrhea	581	6392	489	5938
Female age 18-25	53	683	35	550
Female age ≤ 17	3	90	1	79
Male rectal gonorrhea	151	1532	129	1419
Early Syphilis (adult total)	78	1009	37	658
Primary	9	150	2	99
Secondary	23	301	11	183
Early latent	46	558	24	376
Congenital syphilis	1	33	2	33

* Cumulative case count of the previous 12 months.

Table 2. Selected STD Cases and Annualized Rates per 100,000 Population for San Diego County by Age and Race/Ethnicity, Year-to-Date.

	All Races*		Asian/PI		Black		Hispanic		White	
	cases	*rate*	*cases*	*rate*	*cases*	*rate*	*cases*	*rate*	*cases*	*rate*
All ages										
Chlamydia	1340	488.7	31	89.2	59	458.4	146	153.2	185	155.9
Gonorrhea	489	178.3	24	69.0	31	240.9	109	366.1	91	76.7
Early Syphilis	37	13.5	3	8.6	5	38.8	16	16.8	11	9.3
Under 20 yrs										
Chlamydia	218	319.0	0	0.0	9	285.3	13	43.7	33	139.3
Gonorrhea	24	35.1	2	27.7	7	221.9	4	13.4	1	4.2
Early Syphilis	1	1.5	0	0.0	1	31.7	0	0.0	0	0.0

Note: Rates are calculated using 2023 Population Estimates; County of San Diego, Health and Human Services Agency, Public Health Services Division, Community Health Statistics Unit. 01/2025.

* Includes cases designated as "other," "unknown," or missing race/ethnicity.

Note: All data are provisional. *Case counts are based on the earliest of date of diagnosis, date of specimen collection, and treatment date. Totals for past months might change because of delays in reporting from labs and providers.*

Figure 1. Chlamydia and Gonorrhea Reported Among County of San Diego Residents, by 3-Month Period.



Figure 2. Early Syphilis Reported Among County of San Diego Residents, by 3-Month Period.



Editorial Note: Twice-Yearly Lenacapavir Approved for HIV-1 Pre-Exposure Prophylaxis

On June 18, 2025, the Food and Drug Administration (FDA) approved the long-acting injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor lenacapavir (marketed by Gilead Sciences as Yeztugo®) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35 kg (77 lbs). The approval was based on data from two Phase 3 clinical trials, the PURPOSE-1 and PURPOSE-2 studies, in which ≥99.9% of participants who received Yeztugo® remained HIV-negative [1]. The PURPOSE-1 trial enrolled cisgender women in sub-Saharan Africa, and the PURPOSE-2 trial enrolled a geographically diverse population of cisgender men and gender-diverse people. Yeztugo® is the first and only twice-yearly PrEP option available in the United States. Full prescribing information for Yeztugo® is available here.

Lenacapavir (Yeztugo®) is the fourth medication overall and the second injectable medication that has been approved by the FDA for HIV PrEP. Cabotegravir (APRETUDE, ViiV Healthcare) was approved by the FDA for PrEP in 2021 and is given as an intramuscular injection at day 0 and at one month and every two months thereafter [2]. There are two oral PrEP options, including fixed-dose combinations of emtricitabine and tenofovir disoproxil fumarate (F/TDF, available as Truvada® and generic formulations) and emtricitabine and tenofovir alafenamide (F/TAF, available as Descovy®, Gilead Sciences). F/TAF is currently not FDA-approved for PrEP for people assigned female at birth who are vulnerable to acquiring HIV through vaginal or front-hole exposure. However, the International Antiviral Society-USA (IAS-USA) expert panel recommends F/TAF for prevention of HIV acquisition from vaginal exposures for those in whom F/TDF is contraindicated or undesirable [3].

While the most recent Centers for Disease Prevention and Control (CDC) PrEP guidelines were released in 2021, IAS-USA recently published updated PrEP guidance that includes lenacapavir.

County of San Diego STD Clinics: www.STDSanDiego.org
Phone: (619) 692-8550 **Fax:** (619) 692-8543
STD Clinical Consultation Line: (619) 609-3245 (8am-5pm, M–F)

Provider STD Reporting: (619) 692-8520; fax (619) 692-8541
Sign up to receive Monthly STD Reports, email STD@sdcounty.ca.gov